Hopes for HIV vaccine buoyed by start of second big trial

Scientists announced the launch of another large HIV vaccine efficacy study on Thursday, fueling hopes for a protective shot against the virus of which causes AIDS, despite past disappointments.

The start of the brand-new trial involving 2,0 women in southern Africa means of which for initially in more than a decade there are at This specific point two big HIV vaccine clinical trials taking place at the same time.

The brand-new study will be testing a two-vaccine combination developed by Johnson & Johnson with the U.S. National Institutes of Health (NIH) as well as the Bill & Melinda Gates Foundation. The first vaccine, also backed by NIH, began a trial last November.

Both studies aim to build on the modest success of a previous trial in Thailand in 2009, when an earlier vaccine showed a 31-percent reduction in infections.

“We’re producing progress,” said J&J Chief Scientific Officer Paul Stoffels, who believes This specific should be possible to achieve effectiveness above 50 percent.

“of which will be the goal. Hopefully, we get much higher,” he told Reuters.

The brand-new vaccines require one dose to prime the immune system as well as a second shot to boost the body’s response.

Significantly, J&J’s latest vaccine uses so-called mosaic technology to combine immune-stimulating proteins coming from different HIV strains, representing different types of virus coming from around the entire world, which should produce a “global” vaccine.

One reason why producing an HIV vaccine has proved so difficult from the past will be the variability of the virus.

Although modern HIV drugs have turned the disease coming from a death sentence into a chronic condition, a vaccine will be still seen as critical in rolling back the pandemic, since the number of people infected will be still growing.

Some 37 million individuals around the entire world currently have HIV as well as around 1.8 million became newly infected last year.

For the brand-new study, sexually active women in South Africa, Malawi, Mozambique, Zambia as well as Zimbabwe will be given the experimental vaccine or a placebo as well as then followed for three years to see if This specific prevents infections.

Initial clinical results reported at an AIDS conference in Paris in July showed the mosaic vaccine was safe as well as elicited a Great immune response in healthy volunteers.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

15 − eleven =